Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Q-linea AB ( (SE:QLINEA) ) has issued an announcement.
Q-linea AB has announced the appointment of Stuart Gander as the new CEO, with Anders Ljunggren transitioning to the role of deputy CEO. This leadership change is seen as a natural progression, given Gander’s prior role as president of the Q-linea group and his recent residency in Sweden, which aligns with the company’s strategic goals and operational continuity.
The most recent analyst rating on (SE:QLINEA) stock is a Hold with a SEK51.00 price target. To see the full list of analyst forecasts on Q-linea AB stock, see the SE:QLINEA Stock Forecast page.
More about Q-linea AB
Q-linea is a company specializing in rapid antimicrobial susceptibility testing (AST) systems, particularly known for its ASTar® system. This system aids hospitals in quickly determining optimal antimicrobial therapies for patients with bloodstream infections and sepsis, thereby improving treatment outcomes. Headquartered in Uppsala, Sweden, Q-linea also has regional offices in Italy and the USA, and maintains partnerships worldwide.
YTD Price Performance: -70.91%
Average Trading Volume: 13,005
Technical Sentiment Signal: Sell
Current Market Cap: SEK173.5M
For detailed information about QLINEA stock, go to TipRanks’ Stock Analysis page.